Does the media prefer EDIT or BEAM?

In the previous week, Beam Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Beam Therapeutics and 1 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 1.20 beat Editas Medicine's score of 1.16 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRSP or EDIT?

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Editas Medicine. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat CRISPR Therapeutics' score of 0.68 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EDIT or NTLA?

In the previous week, Intellia Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 4 mentions for Intellia Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Intellia Therapeutics' score of 0.86 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMTX or EDIT more profitable?

Editas Medicine has a net margin of -281.59% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Immatics -572.35% -47.36% -39.35% Editas Medicine -281.59% -677.39% -58.25%

Does the media prefer IMTX or EDIT?

In the previous week, Immatics had 1 more articles in the media than Editas Medicine. MarketBeat recorded 2 mentions for Immatics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Immatics' score of 0.93 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRVS or EDIT?

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Corvus Pharmaceuticals' score of 1.07 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Editas Medicine (EDIT) Competitors

$2.98 +0.10 (+3.47%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$2.97 -0.01 (-0.34%)

As of 07/17/2026 06:21 PM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, IMTX, and CRVS

Should you buy Editas Medicine stock or one of its competitors? MarketBeat compares Editas Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Immatics (IMTX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Editas Medicine compare to Beam Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

In the previous week, Beam Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 3 mentions for Beam Therapeutics and 1 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 1.20 beat Editas Medicine's score of 1.16 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Editas Medicine currently has a consensus target price of $5.40, suggesting a potential upside of 81.21%. Beam Therapeutics has a consensus target price of $46.85, suggesting a potential upside of 70.16%. Given Editas Medicine's higher possible upside, equities research analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.20	-$160.06M	-$1.23	N/A
Beam Therapeutics	$139.74M	20.27	-$79.99M	-$0.68	N/A

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Beam Therapeutics beats Editas Medicine on 15 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,312.93	-$581.60M	-$6.22	N/A
Editas Medicine	$40.52M	7.20	-$160.06M	-$1.23	N/A

CRISPR Therapeutics currently has a consensus price target of $67.78, suggesting a potential upside of 41.85%. Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 81.21%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Editas Medicine. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat CRISPR Therapeutics' score of 0.68 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market.

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

In the previous week, Intellia Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 4 mentions for Intellia Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Intellia Therapeutics' score of 0.86 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Editas Medicine currently has a consensus price target of $5.40, indicating a potential upside of 81.21%. Intellia Therapeutics has a consensus price target of $20.19, indicating a potential upside of 77.39%. Given Editas Medicine's stronger consensus rating and higher probable upside, research analysts clearly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Editas Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.20	-$160.06M	-$1.23	N/A
Intellia Therapeutics	$67.67M	23.50	-$412.69M	-$3.54	N/A

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Immatics?

Immatics (NASDAQ:IMTX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Editas Medicine has a net margin of -281.59% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, Immatics had 1 more articles in the media than Editas Medicine. MarketBeat recorded 2 mentions for Immatics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Immatics' score of 0.93 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.4% of Immatics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

Immatics presently has a consensus target price of $20.80, indicating a potential upside of 116.89%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 81.21%. Given Immatics' stronger consensus rating and higher possible upside, equities analysts plainly believe Immatics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Editas Medicine has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	23.55	-$222.26M	-$1.99	N/A
Editas Medicine	$40.52M	7.20	-$160.06M	-$1.23	N/A

Summary

Immatics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Editas Medicine. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Editas Medicine	$40.52M	7.20	-$160.06M	-$1.23	N/A

Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 1.16 beat Corvus Pharmaceuticals' score of 1.07 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 123.71%. Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 81.21%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Corvus Pharmaceuticals is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Corvus Pharmaceuticals has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Corvus Pharmaceuticals' return on equity of -38.92% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Editas Medicine	-281.59%	-677.39%	-58.25%

Summary

Corvus Pharmaceuticals beats Editas Medicine on 10 of the 15 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$291.76M	$3.69B	$7.01B	$12.29B
Dividend Yield	N/A	2.17%	2.67%	9.35%
P/E Ratio	-2.42	21.21	27.28	23.90
Price / Sales	7.20	304.47	527.75	91.70
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	10.64	8.28	10.70	6.18
Net Income	-$160.06M	$23.81M	$3.59B	$332.02M
7 Day Performance	-8.59%	-3.47%	-2.20%	-2.05%
1 Month Performance	10.78%	2.69%	1.63%	-2.18%
1 Year Performance	7.97%	45.93%	25.64%	17.67%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	2.8194 of 5 stars	$2.98 +3.5%	$5.40 +81.2%	+8.0%	$291.76M	$40.52M	N/A	230	News Coverage Positive News Gap Down
BEAM Beam Therapeutics	3.5062 of 5 stars	$30.89 -0.4%	$46.85 +51.7%	+32.7%	$3.19B	$139.74M	N/A	510	Positive News Gap Down
CRSP CRISPR Therapeutics	3.4075 of 5 stars	$50.46 -0.3%	$67.78 +34.3%	-26.6%	$4.88B	$3.51M	N/A	460	News Coverage Gap Down
NTLA Intellia Therapeutics	3.3088 of 5 stars	$13.30 +2.2%	$20.67 +55.4%	-5.6%	$1.82B	$67.67M	N/A	600	Analyst Downgrade
IMTX Immatics	2.2792 of 5 stars	$9.35 +1.3%	$20.80 +122.5%	+59.8%	$1.24B	$54.60M	N/A	260	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, IMTX, and CRVS

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Immatics?

Summary

How does Editas Medicine compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, IMTX, and CRVS

How does Editas Medicine compare to Beam Therapeutics?

Does the media prefer EDIT or BEAM?

Which has more volatility & risk, EDIT or BEAM?

Do analysts rate EDIT or BEAM?

Do insiders & institutionals have more ownership in EDIT or BEAM?

Which has better earnings and valuation, EDIT or BEAM?

Is EDIT or BEAM more profitable?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Which has stronger earnings and valuation, CRSP or EDIT?

Do analysts rate CRSP or EDIT?

Do institutionals and insiders have more ownership in CRSP or EDIT?

Is CRSP or EDIT more profitable?

Does the media prefer CRSP or EDIT?

Which has more risk and volatility, CRSP or EDIT?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Is EDIT or NTLA more profitable?

Does the media refer more to EDIT or NTLA?

Which has more volatility and risk, EDIT or NTLA?

Do analysts rate EDIT or NTLA?

Do institutionals & insiders believe in EDIT or NTLA?

Which has stronger earnings and valuation, EDIT or NTLA?

Summary

How does Editas Medicine compare to Immatics?

Is IMTX or EDIT more profitable?

Does the media prefer IMTX or EDIT?

Do insiders & institutionals have more ownership in IMTX or EDIT?

Which has more volatility and risk, IMTX or EDIT?

Do analysts prefer IMTX or EDIT?

Which has higher earnings and valuation, IMTX or EDIT?

Summary

How does Editas Medicine compare to Corvus Pharmaceuticals?

Which has stronger earnings & valuation, CRVS or EDIT?

Which has more risk & volatility, CRVS or EDIT?

Do insiders & institutionals hold more shares of CRVS or EDIT?

Does the media prefer CRVS or EDIT?

Do analysts recommend CRVS or EDIT?

Is CRVS or EDIT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools